Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Novel / V-substituted indolyl-3-glyoxylic acid amides their use as medicaments and processes for their preparation
• tumors are a fundamental disease of higher organisms in the plant, animal and human kingdoms.
• the generally recognized multi-step model of cancer development assumes that the accumulation of several mutations in a single cell changes their proliferation and differentiation behavior in such a way that a malignant state with metastasis is ultimately achieved via benign intermediates.
• the term cancer or tumor hides a clinical picture with more than 200 different individual diseases. Tumor diseases can be benign or malignant.
• the main tumors are those of the lungs, breast, stomach, cervix, prostate, head and neck, colon and rectum, liver and blood system.
• Indolyl-3-glyoxylic acid amides are widely used as pharmacologically active compounds and as synthesis building blocks in pharmaceutical chemistry.
• WO03 / 022280 describes N-substituted alkyl- or aryl-3-glyoxylic acid amidindoles with antitumoral activity. However, specific examples of this substitution pattern on the glyoxylamide nitrogen atom are not given.
• W099 / 55696 A1 describes substituted hydroxyindoles as phosphodiesterase 4 inhibitors.
• An antitumor activity for the compounds according to the invention is neither described nor suggested.
• WO 02/08225 A1 describes 2- (1 H-indol-3yl) -2-oxoacetamide derivatives with anti-tumor activity against solid tumors.
• specific embodiments with substitution on the glyoxylamide nitrogen atom are not the subject of the application.
• Patent specification WO 00/67802 describes indole-3-glyoxylamides which are substituted with higher-chain fatty acids as potential antitumor agents. However, specific exemplary embodiments are not given or are backed up with biological data.
• N-heterocyclic indolylglyoxylamides are described as orally active compounds with antitumoral activity.
• Applicant's WO 02/10152 A2 already describes another class of indole derivatives for the treatment of tumors.
• the active ingredient N- (2-methyl-6-quinolyl) - [1 - (4-chlorobenzyl) indol-3-yl] glyoxylic acid amide was tested for its anti-proliferative effect on various tumor cell lines.
• the present invention relates to new N-substituted indolyl-3-glyoxylic acid amides, their production and use as medicaments for the treatment of benign and malignant tumor diseases in humans and mammals.
• Hydrogen unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl, amino, mono-alkylamino, , Halogen, alkyl substituted with one or more fluorine atoms, preferably trifluoromethyl group, cyano, straight-chain or branched cyanoalkyl, Alkylcarbonyl, carboxyl, alkoxycarbonyl, carboxyalkyl or alkoxycarbonylalkyl, alkoxy, arylalkoxy, preferably benzyloxy, alkoxycarbonylamino, alkoxycarbonylaminoalkyl,
• R2 denotes unsubstituted or substituted alkyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl,
• R7 a sulfone of the formula -S02-X1, where X1 is N (alk) 2 , hydroxyl,, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, are unsubstituted or substituted alkyl heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl;
• X2 is unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylaryl and unsubstituted or substituted alkylheteroaryl,
• X3 is unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted alkyl heterocyclyetero, and unsubstituted or substituted mean,
• NX4X5 where X4 and X5 independently of one another are hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted Heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted alkyl heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroalkyl, or X4 and X5 together, or X4 and X5, cyclo
• X6 and X7 independently of one another are hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, or unsubstituted or substituted
• O, S or geminally linked hydrogen and hydroxy means O or S.
• HET for one or more heteroatoms selected from the group
• N, 0 and S containing saturated, unsaturated or aromatic (C2-C14) heterocycle which is connected to the amide nitrogen directly or via a (C1-C6) alkyl bridge and the alkyl radical can be substituted or unsubstituted and optionally on the heterocycle or two aryl or cycloalkyl groups can be fused, and the heterocycle, aryl or cycloalkyl groups can be unsubstituted or substituted and the alkyl radical can be branched or unbranched and saturated or unsaturated in all cases,
• the substituent HET can in particular pyrrole, furan, thiophene, pyrazole, thiazole, indole, oxazole, imidazole, isothiazole, isoxazole, 1, 2,3-triazole, 1, 2,4-triazole, 1, 2,4, oxadiazole, 1 , 3,4-oxadiazole, 1, 2,5-thiadiazole, 1, 3,4-thiadiazole, tetrazole, pyridine, pyrimidine, pyridazine, pyrazine, benzofuran, indazole, carbazole, benzoxazole, benzimidazole, benzothiazole, benzotriazole, quinoline, isoquinoline , Cinnoline, quinoxaline, quinazoline, phthalazine, pyridopyrazine, 1, 2,3-triazine, 1, 2,4-triazine, 1, 3,5-triazine, purine
• alkyl encompasses acyclic saturated or unsaturated hydrocarbons having 1 to 20 carbon atoms, which can be branched or straight-chain and unsubstituted or mono- or polysubstituted.
• cycloalkyl means cyclic hydrocarbons with 3-12 hydrocarbons, which can be saturated or unsaturated, unsubstituted or substituted one or more times.
• aryl means aromatic hydrocarbons having 6 to 14 carbon atoms, which may be unsubstituted or substituted one or more times, the aryl substituents being the same or different and being present in any and possible position of the aryl.
• heteroaryl stands for a 5-, 6- or 7-membered cyclic aromatic radical which contains at least 1, possibly also 2, 3, 4 or 5 heteroatoms, the heteroatoms being the same or different and the heterocycle being unsubstituted or In the case of substitution on the heteroaryl part, the heteroaryl substituents can be identical or be different and stand in any and possible position of the heteroaryl.
• Preferred heteroatoms are nitrogen, oxygen and sulfur.
• heterocyclyl stands for a 3-, 4-, 5-, 6-, 7- or 8-membered cyclic organic radical which contains at least 1, optionally 2, 3, 4 or 5 heteroatoms, the heteroatoms being the same or are different and the cyclic radical is saturated or unsaturated but not aromatic and can be unsubstituted or mono- or polysubstituted, preferred heteroatoms are nitrogen, oxygen and sulfur.
• alkyl-cycloalkyl alkyl-heterocyclyl
• alkylaryl or alkylheteroaryl
• alkyl and cycloalkyl, heterocyclyl, aryl and heteroaryl have the meanings mentioned and the cycloalkyl-, heterocyclyl-, aryl- or heteroaryl- Radical is bonded via a C1-C8-alkyl group to the compound of general formula I.
• alkyl the term substituted in the sense of this invention means the substitution of a hydrogen radical by F, Cl, Br, I, CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2 , SH, S-alkyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl, S-heterocyclyl, S-alkyl -OH, S- alkyl-
• one or more substituted means the one or more, for example two, three or four times, substitution of one or more hydrogen atoms of the ring system by F, Cl , Br, I, CN, NH 2 , NH-alkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , NC (0) alkyl, N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2 , SH, S-alkyl, S -Aryl, S-heteroaryl, S-alkyl-aryl
• the erfi 'ndungswashen compounds of general formula I may be in the form of their racemates, in the form of the pure enantiomers and / or diastereomers or in the form of mixtures of these enantiomers and / or diastereomers, namely both in substance as also as pharmaceutically acceptable salts of these compounds.
• the mixtures can be present in any mixing ratio of the stereoisomers.
• the compounds according to the invention can be in the form of the tautomers.
• the compounds of the general formula I according to the invention if they have a sufficiently basic group, such as, for example, a secondary or tertiary amine, can be converted into salts with inorganic and organic acids.
• the salts formed include hydrochlorides, hydrobromides, sulfates, phosphates, methanesulfonates, sulfoacetic acid, tosylates, carbonates, bicarbonates, formates, acetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, mandelates, fumarates , Lactates, citrates and glutaminates.
• the stoichiometry of the salts formed of the compounds according to the invention can be integer or non-integer multiples of one.
• the compounds of general formula I according to the invention if they contain a sufficiently acidic group, such as the carboxy group, can be converted into their physiologically tolerable salts with inorganic and organic bases.
• inorganic bases are sodium hydroxide, potassium hydroxide, calcium hydroxide, and organic bases are ethanolamine, diethanolamine, triethanolamine, cyclohexylamine,
• Dibenzylethylenediamine and lysine are considered.
• the stoichiometry of the salts formed of the compounds according to the invention can be integer or non-integer multiples of one.
• Solvates and in particular hydrates of the compounds according to the invention which, for. B. can be obtained by crystallization from a solvent or from aqueous solution.
• One, two, three or any number of solvate or water molecules can combine with the compounds according to the invention to form solvates and hydrates.
• Most preferred are compounds according to general formula I, which are made in the following selection:
• the indolyl-3-glyoxylic acid amides according to general formula I are suitable as active ingredients in medicaments, in particular as anti-tumor agents, for the treatment of humans and mammals.
• Mammals can be pets such as horses, cows, dogs, cats, rabbits, sheep and the like.
• a method for combating tumors in humans and in mammals which is characterized in that at least one indolyl-3-glyoxylic acid amide according to general formula I is effective in humans or a mammal for the treatment of tumors Amount is administered.
• the therapeutically effective dose of the respective indolyl-3-glyoxylic acid amide according to the invention to be administered for the treatment is determined inter alia. according to the type and stage of the tumor, the age and sex of the patient, the type of administration and the duration of treatment.
• the pharmaceuticals according to the invention can be administered as liquid, semi-solid and solid pharmaceutical forms.
• the pharmaceutical forms optionally contain auxiliaries, such as, depending on the galenic form used including solvents, accelerators, solubilizers, emulsifiers, wetting agents, anti-foaming agents, gel formers, thickeners, film formers, binders, buffers, salt formers, drying agents,
• auxiliaries such as, depending on the galenic form used including solvents, accelerators, solubilizers, emulsifiers, wetting agents, anti-foaming agents, gel formers, thickeners, film formers, binders, buffers, salt formers, drying agents,
• Flow regulators fillers, preservatives, antioxidants, dyes, mold release agents, lubricants, disintegrants, taste and smell correctors.
• the selection of the auxiliaries and the amounts to be used depends on the galenic form chosen and is based on the recipes known to the person skilled in the art.
• the medicaments according to the invention can be applied to the skin in a suitable dosage form, epicutaneously as a solution, suspension, emulsion, foam, ointment, paste or plaster; via the oral and tongue mucosa, buccal, lingual or sublingual as a tablet, lozenge, dragees, linctus or gargle water; via the gastric and intestinal mucosa, enterally as tablets, coated tablets, capsules, solutions, suspensions or emulsions; via the rectal mucosa, rectally as a suppository, rectal capsule or ointment; through the nasal mucosa, nasally as drops, ointments or spray; via the bronchial and alveolar epithelium, pulmonary or by inhalation as aerosol or inhalation; via the conjunctiva, conjunctival as eye drops, eye ointment, eye tablets, lamellae or eyewash; via the mucous membranes of the genital organs,
• the compounds of general structure I according to the invention can be extended with regard to practical therapeutic requirements by means of suitable measures in their drug action. This goal can be achieved chemically and / or galenically. Examples of achieving an increase in activity are the use of implants, liposomes, slow-release forms, nanoparticle suspensions and so-called prodrugs of the invention Compounds, the formation of sparingly soluble salts and complexes or the use of crystal suspensions.
• the compounds according to the invention can be used as a single substance or in combination with other cytotoxic substances, e.g. Cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate and in particular in combination with signal transduction inhibitors, such as e.g. Herceptin, Glivec or Iressa can be used.
• cytotoxic substances e.g. Cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate
• signal transduction inhibitors such as e.g. Herceptin, Glivec or Iressa
• Drugs which contain at least one compound from the following group of indolyl-3-glyoxyl derivatives are particularly preferred:
• the invention further includes methods for preparing the compounds of structure I according to the invention.
• the compounds (I) according to the invention can be synthesized according to Scheme 1 below:
• stages 1 and 2 which are based on synthesis scheme 1
• the following compounds were synthesized, which can be seen from the following overview by specifying the respective chemical name.
• the compounds according to the invention were characterized analytically by their melting points or 1 H-NMR spectroscopy and / or mass spectrometry.
• Example 6 - Inhibition of selected tumor cell lines: Substance 1 was examined in a proliferation test on established tumor cell lines for their anti-proliferative activity (D.A. Scuderio et al. Cancer Res. 1988, 48, 4827-4833). The test used determines the cellular dehydrogenase activity and enables a determination of the cell vitality and indirectly the cell number.
• the cell lines used are the human cervical carcinoma cell line KB / HeLa (ATCC CCL17), the ovarian adeno carcinoma cell line SKOV-3 (ATCC HTB77), the human glioblastoma cell line SF-268 (NCI 503138) and the lung carcinoma cell line NCI- H460 (NCI 503473).
• Table 1 Inhibition of proliferation of the substances according to the invention in the XTT cytotoxicity test on human tumor cells
• substance 1 was investigated against multi-drug-resistant cell lines in comparison to the non-resistant wild-type cell lines.
• the cell lines examined are the murine L1210, the acute myeloid leukemia cell line LT12 and the resistant lines L1210 / mdr and LT12 / mdr.
• the murine P388 cell line methyl-cholanthrene-induced lymphoid neoplasm
• the doxorubicin-resistant P388 were used as test systems.
• Table 2 Inhibitory effect of substance (1) in the XTT proliferation test on human tumor cell lines.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34129467

Family Applications (1)

Country Status (18)

Families Citing this family (2)

Family Cites Families (1)

• 2003
  • 2003-07-25 DE DE10334040A patent/DE10334040A1/de not_active Withdrawn
• 2004
  • 2004-07-09 AU AU2004263238A patent/AU2004263238A1/en not_active Abandoned
  • 2004-07-09 RU RU2006105708/04A patent/RU2317293C9/ru not_active IP Right Cessation
  • 2004-07-09 MX MXPA06000995A patent/MXPA06000995A/es unknown
  • 2004-07-09 EP EP04740854A patent/EP1651600A2/de not_active Withdrawn
  • 2004-07-09 WO PCT/EP2004/007573 patent/WO2005014542A2/de active Application Filing
  • 2004-07-09 BR BRPI0412898-2A patent/BRPI0412898A/pt not_active IP Right Cessation
  • 2004-07-09 RS YUP-2006/0049A patent/RS20060049A/sr unknown
  • 2004-07-09 JP JP2006521430A patent/JP2007503376A/ja not_active Withdrawn
  • 2004-07-09 CN CNA2004800240832A patent/CN1839129A/zh active Pending
  • 2004-07-09 KR KR1020067001636A patent/KR20060037398A/ko not_active Application Discontinuation
  • 2004-07-09 CA CA002533433A patent/CA2533433A1/en not_active Abandoned
  • 2004-07-19 TW TW093121509A patent/TW200524863A/zh unknown
  • 2004-07-23 AR ARP040102632A patent/AR045928A1/es not_active Application Discontinuation
  • 2004-09-07 UA UAA200601216A patent/UA83498C2/uk unknown
• 2006
  • 2006-01-24 IL IL173335A patent/IL173335A0/en unknown
  • 2006-02-13 ZA ZA200601300A patent/ZA200601300B/xx unknown
  • 2006-02-14 NO NO20060697A patent/NO20060697L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events